Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065011 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
A Phase 2 study of Usher's Syndrome, sponsored by Sanofi.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT02065011 is a Phase 2 study of Usher's Syndrome that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 9 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02065011, a Phase 2 study of Usher's Syndrome, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
Conditions Studied
Interventions
- DRUG Blood draw for the laboratory assessment
Study Locations (2)
Oregon
- Oregon Health and Science University Site Number : 840001 - Portland
Other
- Investigational Site Number : 250001 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-09-12 |
| Est. Completion | 2031-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065011
The ClinicalTrials.gov registry entry for NCT02065011 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Usher's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for the laboratory assessment is the first listed.
NCT02065011 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Other.
Frequently Asked Questions
What is clinical trial NCT02065011 about?
NCT02065011 is a clinical study titled "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B". Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
What is the current status of trial NCT02065011?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-09-12. Estimated completion is 2031-06-13.
What conditions does trial NCT02065011 study?
This clinical trial studies the following conditions: Usher's Syndrome.
What interventions are being tested in trial NCT02065011?
The interventions under investigation include: Blood draw for the laboratory assessment (DRUG).
Who is sponsoring clinical trial NCT02065011?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065011 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.